Wei Kang sat in the office, frowning as he looked at the experimental report in front of him.
The clinical phase III trial report of the thalassemia gene drug has finally come out.
The data were perfect and all patients had great success with their first treatment.
Patients in the first clinical phase have received the second treatment, and the hemoglobin in their bodies has remained normal for a long time.
This means that the patient's thalassemia has been completely cured and a third treatment may not be needed.
There are more than 500 Phase III patients in Huaxia and Yingguo, and there are also 500 patients in Phase I and II.
As a result, the total number of people participating in clinical trials has exceeded 1,000, fully meeting the FDA's rapid application requirements for new drugs.
Sanqing will soon announce the official launch of this drug in Eagle Country.
As for China, it will have to move more slowly. It is estimated that it will be approved for listing in another month or two.
However, Wei Kang was still a little worried. He wanted to ensure that there would be no mistakes before going public.
Because this new drug launch journey was so smooth. Not only the painkillers were successfully launched in Eagle Country, they were sold very well.
Treatment appointments for new thalassemia drugs in major hospitals in Eagle Country have been scheduled for three months.
Everything looks perfect and ready for launch.
Wei Kang thought for a long time and pulled out the patent information from the computer.
Thalassemia gene drugs have registered drug-related patents in China and Eagle Country, so there is no problem with this.
As for the patent rights for CRISPR gene editing technology, the China Intellectual Property Office awarded it to a research team at the University of California, which is the team of Nobel Prize winner Dr. Doudna.
The European Patent Office also approved the University of California’s patent with broad claims.
Apparently, the University of California owns the patent for this gene-editing technology.
Therefore, Sanqing also contacted the University of California team during the new drug approval process and obtained the other party's patent license.
For academic researchers, this technology can be used without hindrance as long as they do not profit from the results.
But for commercial organizations, obtaining patent licenses is quite expensive, and an agreement must be reached with the patent owner.
Sanqing has already taken this into consideration. After obtaining the patent license, it has already negotiated the price with Dr. Doudna’s team.
However, this patent seems to be a bit troublesome in Eagle Country, and it has been involved in a protracted patent battle.
The thing is, after the University of California team published a paper in Science magazine in 2012 that the "gene magic scissors" Crispr-Cas9 can accurately cut DNA in test tubes, they had not yet had time to apply for a patent from the Eagle Country Patent Office.
Another institution took notice and took action. Zheng Feng's team at the Broad Institute took the lead in realizing the gene editing of this technology in human cells and immediately applied for a patent.
Although both teams submitted patent applications at the same time, the Broad Institute applied for a fast track and was the first to be granted a patent for the CRISPR system for editing eukaryotic cells.
However, the University of California's patent application for CRISPR-Cas9 for editing all types of cells including bacteria, plants, animals and humans has not been approved and even faces the consequences of being returned.
The University of California did not give up easily. They have been fighting a lawsuit with the Broad Institute to compete for patent ownership.
After Doudna's team won the Nobel Prize, they also established their status as orthodox inventors.
They have received support from patent offices in China, Europe and other countries and obtained patent rights.
Only in Eagle Country, the two sides have fallen into a quagmire of patent battles and have been unable to reach a conclusion.
The latest news is that the Eagle Country Patent Office rejected the application of the University of California and awarded the CRISPR patent to the Broad Institute. However, the University of California is obviously not convinced and is already holding back its big move.
It is said that they are ready to seek legal solutions to the judgment of the Eagle Country Patent Office. Especially after obtaining patent authorizations from China and Europa, they are more confident and are filing an appeal to the Eagle Country Federal Court.
It is obvious that the interests involved in CRISPR gene editing technology are huge, and neither team will give up.
The Doudna team at the University of California has the support of Europa, while the Broad Institute is backed by interest groups from the Eagle Country.
The two sides are fighting to the death. It seems to be a tie at present, and it will be difficult to determine the winner in a short time.
Therefore, many commercial organizations that need patent authorization for this technology are quietly waiting for the final result.
Fortunately, in other regions, the Chinese and European Patent Offices have decided on patent ownership early, so for patent authorization in these countries and regions, just contact the University of California team directly.
But in Eagle Country, the war is raging, and it is temporarily unclear which side to vote for.
What if one party obtains a patent authorization and the other party wins the lawsuit?
Isn't it true that all the water in a bamboo basket is empty?
Therefore, no one dares to act rashly for the time being, and Sanqing is no exception.
We can only take it one step at a time. If either party has objections to this, wait until the other party comes to see us.
After all, no one wants to pay two patent licensing fees at the same time.
Wei Kang rubbed his eyebrows and finally felt relieved.
It should be fine, it's completely legal and compliant, no problems can be found.
If there is a problem, it's not his problem.
The next day, Sanqing officially announced the launch of thalassemia genetic medicine in Eagle Country.
The price is also in line with Sanqing's consistent style, expensive in a word.
However, this did not have much impact on the influx of patients.
Sanqing has previously launched genetic drugs in Eagle Country, such as SMA and Menkes genetic drugs, both priced at US$300,000.
Although due to technical complexity, the price of thalassemia gene drugs has risen to US$500,000.
But compared with the cost of bone marrow transplantation in Eagle Country, which often costs two to three million US dollars, this price is already quite friendly.
Instead, Yingguo netizens continued to praise Sanqing on the Internet.
Twitter, Facebook, etc., these platforms are full of praise for Sanqing.
"Thank God, I can finally be a normal person and no longer have to have blood transfusions every week."
"It is said that Chinese companies are price butchers, and they are indeed right. Sanqing is truly a breath of fresh air among pharmaceutical companies, and its charges are very reasonable."
"I have made an appointment with the Sanqing gene drug treatment at the hospital. The entire treatment process will last one or two months, but the price is still affordable. My insurance can reimburse 70% of the cost, and I can get one for 150,000 US dollars. A healthy body is the most worthwhile money I have spent.”
"The brother upstairs must have a good job. It's really enviable."
"Since Sanqing began to develop genetic drugs, I have never seen drugs priced at millions of dollars. This is really gratifying for patients around the world."
"You think, if Sanqing becomes the world's number one pharmaceutical company, can we be freed from the hell of high-priced drugs?"
"It's very possible that that will be good news for all mankind, and we will completely enter heaven."
****
"Haha, stupid humans are just a bunch of idiots. A little favor can win over a lot of people's hearts."
Sol looked at the praise for Sanqing on the Internet and was so angry that his beard couldn't help trembling.
It's a pity that these exaggerated praises are everywhere on the Internet. Anyone who goes online can see them and there is no way to avoid them.
He quickly made a call.
"How is your evidence collection going?"
"It went very well. The hospital intercepted some genetic drugs as evidence, which contained the presence of CRISPR-Cas9 preparations. The evidence is conclusive and is enough to file a lawsuit."
"Haha, don't worry, we'll wait until the first batch of patients have finished their treatment and paid the money."
"clear."
"The big patent stick in my hand is already ready to move."
Sol couldn't help but let out a weird laugh, his voice was extremely comfortable.
He seemed to see the scene of Sanqing being wiped out into ashes under an iron fist.
Like a delicate and beautiful girl, she was ravaged at the hands of thugs.
After staying in this position for a long time, he has an innate, believer-like enthusiasm for destroying any beautiful things.
The more enthusiastic netizens praise Sanqing, the greater the pleasure brought by destroying it.
7017k
